Job title: Executive Director, Global Head of Safety Biomarkers & Translational Sciences Drug Safety R&D
Since 2008, Shashi has been employed by Pfizer, overseeing translational biomarker strategies for developing innovative medicines. Currently, Shashi is the Executive Director and Global Head of Safety Biomarkers and Translational Sciences within Drug Safety R&D, Pfizer Inc. In his current role, responsible for Safety Biomarker activities across all DSRD sites and for establishing and maintaining scientific strategy and operations group across global biomarker groups. Shashi is leading several precompetitive consortia (IMI, PSTC) involving biomarkers and safety biomarker initiatives.
During his 20 years of combined academic and pharmaceutical industry experience, Shashi has delivered over 50 invited seminars and written more than 45 peer-reviewed publications and over 15 book chapters including serving on editorial board of peer reviewed journals and leadership within scientific societies.
Shashi Ramaiah completed his PhD from University of Louisiana at Monroe in Pharmacology and Toxicology. After completing his PhD, Shashi enrolled in the Clinical Pathology residency program at University of Florida and completed his certification in Veterinary Clinical Pathology. Following his residency training, Shashi accepted a tenure track faculty position in the department of Veterinary Pathobiology, College of Veterinary Medicine at Texas A&M University. During his ~6 yr stint as a faculty at Texas A&M, Shashi pursued his independent research on an NIH-NIAAA funded research grant on alcoholic hepatitis and non alcoholic fatty liver syndrome. In addition to his research, Shashi participated in diagnostic clinical pathology service, residency training and graduate student teaching at Texas A&M University.
Session Q&A 12:00 pm
Ask the expert speakers from this session all your burning questionsRead more
day: Day Two
Safety Biomarkers: Application, Challenges & Opportunities 11:20 am
Exploring specific case examples of safety biomarker use Discussing the complexities of novel biomarker discovery, validation and regulatory qualifications needed for broader clinical trial applicationsRead more
day: Day Two